Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

Vertex (VRTX) delivered earnings and revenue surprises of -0.25% and 5.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...